Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer.

Dasanu CA, Lippman SM, Plaxe SC.

J Oncol Pharm Pract. 2017 Dec;23(8):638-640. doi: 10.1177/1078155216674355. Epub 2016 Oct 18.

PMID:
27824586
2.

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.

Li H, Ma W, Yoneda KY, Moore EH, Zhang Y, Pu LL, Frampton GM, Molmen M, Stephens PJ, Li T.

J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z.

3.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.

4.

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.

Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R.

Oncologist. 2016 May;21(5):634-42. doi: 10.1634/theoncologist.2015-0507. Epub 2016 Mar 16.

5.

Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.

Rivera N, Boada A, Bielsa MI, Fernández-Figueras MT, Carcereny E, Moran MT, Ferrándiz C.

JAMA Dermatol. 2017 Nov 1;153(11):1162-1165. doi: 10.1001/jamadermatol.2017.2106.

6.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

7.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR.

N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.

8.

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.

Lim JS, Soo RA.

Ther Adv Respir Dis. 2016 Oct;10(5):444-54. doi: 10.1177/1753465816661091. Epub 2016 Jul 31. Review.

9.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.

PMID:
28407039
10.

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.

Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohé C.

Lung Cancer. 2016 Sep;99:117-9. doi: 10.1016/j.lungcan.2016.06.025. Epub 2016 Jul 1.

PMID:
27565924
11.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Nishijima TF, Shachar SS, Nyrop KA, Muss HB.

Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8. Review.

12.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR.

N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.

13.

Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.

Uenami T, Hosono Y, Ishijima M, Kanazu M, Akazawa Y, Yano Y, Mori M, Yamaguchi T, Yokota S.

Lung Cancer. 2017 Jul;109:42-44. doi: 10.1016/j.lungcan.2017.04.019. Epub 2017 Apr 27.

PMID:
28577948
14.

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V.

J Clin Oncol. 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Epub 2016 Feb 16. Review.

PMID:
26884577
15.

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.

Ran X, Yang K.

Drug Des Devel Ther. 2017 Jul 3;11:2007-2014. doi: 10.2147/DDDT.S140687. eCollection 2017. Review.

16.

Nivolumab: a review in advanced squamous non-small cell lung cancer.

Keating GM.

Drugs. 2015 Nov;75(16):1925-34. doi: 10.1007/s40265-015-0492-9. Review.

PMID:
26514815
17.

Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases.

Blum V, Müller B, Hofer S, Pardo E, Zeidler K, Diebold J, Strobel K, Brand C, Aebi S, Gautschi O.

Eur J Dermatol. 2018 Feb 1;28(1):78-81. doi: 10.1684/ejd.2017.3209.

PMID:
29336323
18.

Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.

Boils CL, Aljadir DN, Cantafio AW.

Am J Transplant. 2016 Aug;16(8):2496-7. doi: 10.1111/ajt.13786. Epub 2016 Apr 21. No abstract available.

19.

The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.

Villaruz LC, Socinski MA.

Clin Pharmacol Ther. 2016 Sep;100(3):212-4. doi: 10.1002/cpt.385. Epub 2016 Jun 3.

20.

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

O'Kane GM, Labbé C, Doherty MK, Young K, Albaba H, Leighl NB.

Oncologist. 2017 Jan;22(1):70-80. doi: 10.1634/theoncologist.2016-0164. Epub 2016 Aug 17. Review.

Supplemental Content

Support Center